Obesity-related M1 macrophages secrete IL-6 via a JAK/STAT-dependent pathway to promote PD-L1 expression in TNBC, and telmisartan reverses this process by activating peroxisome proliferator-activated receptor (PPAR-γ) and inhibiting NF-κB P65, thus highlighting the potential application in adjuvant TNBC immunotherapy138. This evidence concerns the gene NFKB1 and Obesity.